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Supplementary Materials 
A phenomenological challenge in evaluating depressive symptoms in the context of 
patients with a comorbid inflammatory disorder or cancer is that some of the DSM V 
criteria used to establish the diagnosis of MDD, such as fatigue, may be associated with 
the patients’ primary disease. Here we explore (1) the full SF-36 Mental Health 
Component Score, which includes multiple items expected to be at least partly driven by 
the primary disease, (2) a depressive symptom score derived based on selection of the 
two items that match the DSM V core depressive symptoms of “depressed mood” and 
“anhedonia”, (3) the SF-36 Vitality domain score. These were calculated as follows. 
SF-36 Mental Health Component Score: This is comprised of 14 questions clustered in 
four domains of mental function: vitality, social functioning, role-emotional, and mental 
health. The component score was calculated by inverting individual item scores as 
needed so that larger scores consistently indicated an improvement in mental health, 
summing all 14 item scores and scaling the aggregate score from 0 (worst possible mental 
health score) to 100 (best possible mental health score). 
Depressive Symptom Score: The two cardinal depressive symptoms of the DSM 5 
diagnostic criteria for MDD, namely depressed mood and anhedonia, were assessed by 
the following items of the SF-36 Health Survey 1: “Have you felt downhearted and 
depressed?” and “Have you felt so down in the dumps that nothing could cheer you up?”.  
Different versions of the SF-36 have rated the response to these questions on slightly 
different scales. SF-36 v1 was scored with responses “All of the Time”=0, “Most of the 
Time”=1, “A Good Bit of the Time”=2, “Some of the Time”=3, “A Little of the Time”=4, or 
“None of the Time”=5. In SF-36 v2, the response “A Good Bit of the Time” has been 
removed, and the maximum score per item is 4. To allow aggregation of SF-36 data 
collected on different versions of the questionnaire, item scores were summed and scaled 
from 0 to 100 to create the depressive symptom score. For SF-36 v1: depressive 
symptom score = 100*(MH02+MH04)/10. For SF-36 v2: depressive symptom score = 
100*(MH02+MH04)/8. An increase in the score corresponds to an improvement in 
depressive symptoms. In one study (C0743T09), the Hospital Anxiety and Depression 
Scale (HADS23) was used instead of the SF-36. We analyzed the Depression Score. To 
define patients as having high depressive symptoms, a cutoff of >= 8 was applied2,3.  
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SF-36 Vitality Domain Score: Fatigue-related symptoms are common in MDD and many 
non-psychiatric disorders. The SF-36 vitality domain score was used as a self-reported 
measure of fatigue calculated from 4 questionnaire items asking about subjective 
experience of energy and tiredness. Item responses were inverted as appropriate to 
ensure that higher scores always denoted higher energy, summed and scaled from 0-
100.  
 
Example Statistical Analysis: 
In Supplementary Figure 3, we walk through an example of the analysis performed 
using the C1377T04 sirukumab Trial. First, patients were separated into two groups: 
those with high depressive symptoms at baseline, and those without. As the majority of 
patients did not exhibit high depressive symptoms, and those symptoms were measured 
on a scale that saturates at 100, pooling all patients together would dilute a treatment-
related effect on changes in depressive symptoms (Supplementary Figure 3, left). 
Separate mixed models were fit in patient groups with high depressive or low-depressive 
symptoms at baseline. Dependent variables were the Depressive Symptom score, the 
SF-36 Mental Health Component or the SF-36 Vitality score. Treatment, visit, and 
treatment-by-visit interaction were fixed-effects with visit included as a repeated measure. 
To account for changes in symptoms of the primary disease, the DAS28-CRP was added 
as a time-dependent fixed-effect (Supplementary Figure 3, right). The treatment effect 
was assessed by contrasting the improvement in the treatment arm and the placebo arm. 
A p-value threshold of 0.05 was used to declare statistical significance. The significance 
of the change in depressive symptoms is shown, as is the significance of the treatment 
vs. placebo comparison as described in the methods; which for this study is significant. 
The changes in the mean scores for the treated and placebo arms, were designated DMT 
and DMP, respectively.  
 
 
Heterogeneity of pooled studies 
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Tests for heterogeneity examine the null hypothesis that all studies are examining the 
same effect. The heterogeneity of the studies was estimated by Cochran’s Q statistic, I2 
and tau2 4. 
Cochran’s Q is calculated = ∑ 𝑊$(𝑌$ − 𝑀)*,,$-.  which represents the weighted sum of 
squared deviations between each study’s estimate from the pooled estimate. Wi 
corresponds to the weight of each study, Yi to the effect size for each study, and M the 
pooled estimate of effect size. 
I2 = 100*(Q-df)/Q, represents the percentage of total variation across studies due to 
heterogeneity (range 0-100%, with 0% indicating no observed heterogeneity.  
tau2 =(Q-df)/C, where C= ∑ 𝑊$ − ∑ /012034∑ /02034,$-.  estimates the between study variance in a 
random effects meta-analysis.  
 
Cytokine Biomarkers 
A striking contrast between the studies analyzed here and a typical clinical trial in MDD 
subjects is the high level of inflammatory biomarkers observed in all subjects (Figure 1B, 
Supplementary Table 3). This is not surprising since most patients are undergoing 
treatment for diagnosed inflammatory disorders. For example, in MDD studies, CRP 
thresholds of ≥ 3 or ≥ 5 mg/l have been considered for selecting patients with high levels 
of inflammation 5. In epidemiological studies of MDD, median measurements of CRP have 
been in the range of 1.5-3 mg/l 6,7. Effectively all subjects analyzed here have high levels 
of inflammatory proteins. Interestingly, compared across all studies, the mean CRP level 
among patients entering the study correlated with the percentage of patients within that 
study who manifested high depressive symptoms (Figure 1B). 
Comparisons were made between patient groups with and without high depressive 
symptoms at baseline for baseline levels of serum biomarkers using then Wilcoxon rank 
sum test. Correlations between baseline serum biomarkers and change in depressive 
symptom score were assessed using (partial) Spearman correlation coefficients adjusted 
for baseline disease severity. (Supplementary Table 3) 
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Supplementary Figure 1. A) Definition and calculation of the depressive symptom 
score from two items of the SF-36. Depressive symptom score items are indicated in 
blue (MH02, MH04), the vitality score is shown in green, and the full mental health 
component score in red. B) Scoring of SF-36 v1.0 and v2.0 C) High depressive 
symptom criteria by scale.  
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Supplementary Figure 2. Sensitivity Analyses. Positive results from the main analysis 
in Figure 2 for patients with high depressive symptoms were evaluated for A) The effect 
of the definition for “High Depressive Symptoms”, evaluating more lenient (left) and 
stricter (right) definitions where data were available, as described in the Supplementary 
Methods. B) The individual effects were shown on the two items on the SF-36 composing 
the depressive symptom score to assess differences in effect on anhedonia (left) and 
depressed mood (right). C) The effect on depressive symptom score on primary disease 
responders in the “High Depressive Symptom” cohort is included as a corollary to Figure 
2C. 
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Supplementary Figure 3. Example of analysis of a single data set, the phase 2 study of 
sirukumab for rheumatoid arthritis. Depression total score at baseline and 12 weeks in 
the treated and placebo arms for (left) patients without high depressive symptoms at 
baseline and (right) patients with high depressive symptoms at baseline. The mean 
difference in the placebo (DMP) and treated (DMT) arms, used in the calculation of the 
standardized mean difference, is indicated. Error bars are SEM. 
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A. 
 
B.                                                                        C. 
 
Supplementary Figure 4. Effectors of change in depressive symptom score. A. The 
change in depressive symptom score is calculated as the difference between the score 
at the follow-up timepoint and the baseline score for each study. This is calculated for the 
placebo arm and the pooled treatment arms for each study. Lines connect changes in 
placebo and treatment arms from the same study. Studies are grouped by mechanism of 
action. B. Comparison of placebo DMP and treated DMT is shown for each study, grouped 
by drug. Connected points correspond to data from the same trial. Data from the 
ustekinumab trial using the HADS score are not shown due to the different scale. C. 
Within treated arms, for each study (1 point = 1 study), change in depressive symptom 
score is plotted versus the change in vitality score. D. Correlations between changes in 
raw PASI score (pasichg), depressive symptom score (depchg), mental health 
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component score (depchg_cscore), and vitality score (fatig_chg), for all participants in 
study CO168T44. 
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Supplementary Figure 5. Results of anti-inflammatory intervention on depressive 
symptoms: overall, and by targeted mechanism in all subjects. A. Change in 
depressive symptoms score from baseline to follow-up visit is compared across treated 
and placebo arms. The standardized mean difference is used to compare trials on an 
equivalent metric and compare by mechanism. B. A mixed effects model with repeated 
measures was fit, as described in the Methods, including the primary disease symptom 
scale indicated in Table 1 as an additional repeated measure.  
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Supplementary Figure 6. Results of anti-inflammatory intervention on mental 
health component score: overall, and by targeted mechanism in all subjects. A. 
Change in depressive symptoms score from baseline to follow-up visit is compared 
across treated and placebo arms. The standardized mean difference is used to compare 
trials on an equivalent metric and compare by mechanism. B. A mixed effects model with 
repeated measures was fit, as described in the Methods, including the primary disease 
symptom scale indicated in Table 1 as an additional repeated measure.  
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Supplementary Figure 7. Results of anti-inflammatory intervention on SF-36 vitality 
domain score: overall, and by targeted mechanism in all subjects. A. Change in 
depressive symptoms score from baseline to follow-up visit is compared across treated 
and placebo arms. The standardized mean difference is used to compare trials on an 
equivalent metric and compare by mechanism. B. A mixed effects model with repeated 
measures was fit, as described in the Methods, including the primary disease symptom 
scale indicated in Table 1 as an additional repeated measure.  
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Supplementary Figure 8. Effect of mean study covariate values on overall study 
effect size on depressive symptoms. Each data point represents a single study. The 
y-axis indicates the Standardized Mean Difference (SMD) among patients with high 
depressive symptoms adjusted for primary disease symptom severity (as in Figure 2B), 
the x-axis corresponds to the mean value of the variable indicated within each study at 
baseline.  
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StudyID ClinicalTrials.gov ID or Trial 
Publication 
 
Study 
Drug 
Treated Disease Concomitant 
medications in placebo 
and treated arms 
Janssen Trials 
C0168T37 http://www.nejm.org/doi/full/10.1056/N
EJMoa050516#t=article  
 
Infliximab  Ulcerative Colitis Oral corticosteroids, 6 
mercaptopurine, or 
azathioprine 
C0168T41 http://onlinelibrary.wiley.com/doi/10.100
2/art.21734/full 
Infliximab Rheumatoid Arthritis Methotrexate 
C0168T44  Infliximab Psoriasis None 
C0524T03 NCT00207740 Golimumab Asthma Corticosteroids 
C0524T09 NCT00265083 Golimumab Ankylosing Spondylitis None 
C0743T08 NCT00267969 Ustekinumab Psoriasis None 
C0743T09 NCT00307437 Ustekinumab Psoriasis  None 
C1377T04 NCT00718718 Sirukumab Rheumatoid Arthritis Methotrexate 
MCD2001 NCT01024036 Siltuximab Multicentric 
Castleman’s Disease 
Best Supportive Care 
GlaxoSmithKline Trials 
OFA110634 NCT00603525 Ofatumumab Rheumatoid Arthritis Methotrexate 
OFA110635 NCT00611455  Ofatumumab Rheumatoid Arthritis Methotrexate 
CXA30007 NCT00120900 GW406381 Osteoarthritis-Knee None 
CXA30009 NCT00113308 GW406381 Rheumatoid Arthritis None 
BEL110751 NCT00410384 Belimumab Lupus (SLE) Standard SLE therapy* 
BEL110752 NCT00424476 Belimumab Lupus (SLE) Standard SLE therapy* 
LBS02 NCT00071487 Belimumab Lupus (SLE) Standard SLE therapy* 
KIP112967 http://onlinelibrary.wiley.com/doi/10.100
2/j.1532-2149.2012.00256.x/full 
Losmapimod Neuropathic Pain None 
KIP113049  Losmapimod Neuropathic Pain None 
*Standard SLE therapies includes corticosteroids, anti-malarial agents, non-steroidal anti-inflammatory drugs, cytotoxic agents, 
immunosuppressive or immunomodulatory agents 
 
Supplementary Table 1: Additional clinical trial details. Reference IDs for all 
included clinical trials and details of the concomitant medications allowed per protocol 
as standard of care in placebo and treated arms. Informed consent was obtained from 
all subjects. 
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Study/Strata Arm Age BMI Sex 
(%Female) 
Corticosteroid 
Use (%Yes) 
Significant 
Covariates (HDS 
Adjusted) 
C0168T37 
     
None 
High DS Infliximab 39.4 (13.4) 
 
50 57.1% 
 
Placebo 47 (15) - 52.4 61.9% 
 
Low DS Infliximab 42.9 (14.7) 
 
36.1 56.5% 
 
Placebo 41.2 (13.2) - 34.8 69.6% 
 
C0168T41 
     
None 
High DS Infliximab 51.8 (12.4) 26.7 (5.2) 87.4 63.0% 
 
Placebo 50.2 (11.8) 26 (6.1) 89.2 63.1% 
 
Low DS Infliximab 52.5 (12.4) 27.1 (5.2) 76 56.5% 
 
Placebo 53.2 (12.5) 27.5 (6.1) 83 57.7% 
 
C0168T44 
     
None 
High DS Infliximab 42.5 (13.1) 31.3 (7.7) 55.8 2.6% 
 
Placebo 44.6 (13.3) 30.9 (7.1) 36 0% 
 
Low DS Infliximab 44.1 (12.5) 31.2 (7.1) 31.8 1.1% 
 
Placebo 44.1 (12.1) 31 (6.6) 28.6 1.2% 
 
C0524T03 
     
Age p=0.020 
High DS Golimumab 49.8 (13.8) 29.4 (6.7) 66.7 5.6% 
 
Placebo 56.9(9.5) 27.7 (5.6) 62.5 12.5% 
 
Low DS Golimumab 50.1 (12.3) 30.1 (7.4) 54.3 4% 
 
Placebo 48.5 (12.3) 30.9 (8.6) 51.6 0% 
 
C0524T09 
     
None 
High DS Golimumab 36.9 (10.5) 26.2 (5.7) 21.4 13.5% 
 
Placebo 34.2 (9.6) 23.1 (4.4) 22.2 33.3% 
 
Low DS Golimumab 39.3 (12.2) 26.4 (5.5) 27.1 19.2% 
 
Placebo 41.1 (12.9) 27.1 (6.2) 29.8 16.4% 
 
C0743T08 
     
Age p=0.041 
High DS Ustekinumab 41.5 (13.1) 32.4 (7.1) 38.7 4.5% 
 
Placebo 46 (7.4) 31.5 (6.7) 42.1 0 
 
Low DS Ustekinumab 45.8 (11.8) 31.7 (7.5) 30.8 1.5% 
 
Placebo 44.8 (11.6) 31.4 (7.2) 26.6 1.7% 
 
C0743T09 
     
None 
High DS Ustekinumab 45.4 (11.4) 30.5 (6.9) 41.2 1.4% 
 
Placebo 47.3 (11.5) 31.2 (7.1) 33 0 
 
Low DS Ustekinumab 46.1 (12.2) 30.8 (6.7) 28.8 0.7% 
 
Placebo 46.9 (12.6) 30.42 (6.5) 29.5 1.7% 
 
C1377T04 
     
None 
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High DS Sirukumab 49.4 (11.1) 27.2 (4.7) 85.3 58.8 
 
Placebo 49.3 (9) 28.6 (6.2) 91.7 66.7 
 
Low DS Sirukumab 52.9 (10.9) 26.6 (5.7) 84.5 56.7 
 
Placebo 51.6 (12.2) 26.5 (5.9) 63.6 45.5 
 
MCD2001 
     
None 
High DS Siltuximab 44.8 (13.6) 25.5 (4.8) 45.5 18.2 
 
Placebo 49.3 (14.0) 23.3 (3.4) 25 25 
 
Low DS Siltuximab 43.8 (13.6) 24.4 (3.9) 42.5 32.5 
 
Placebo 47.4 (13.6) 26.5 (5.5) 13.6 31.8 
 
OFA110634  
     
None 
High DS Ofatumumab 52.3 (10.4) 26.7 (6.3) 89 100 
 
Placebo 56.4 (10) 26.9 (4.6) 82 100 
 
Low DS Ofatumumab 53.9 (15.1) 25.2 (4.6) 84 100 
 
Placebo 51.8 (12.4) 26.7 (4.8) 80 100 
 
OFA110635  
     
None 
High DS Ofatumumab 52.7 (9.5) 29 (6.3) 86 100 
 
Placebo 51.7 (11) 27.6 (4.3) 83 100 
 
Low DS Ofatumumab 51.4 (11.9) 27.8 (5) 79 100 
 
Placebo 54 (11.4) 27.4 (5.1) 83 100 
 
CXA30007 
     
None 
High DS GW406381 60.3 (9) 30.4 (6.2) 87 0 
 
Placebo 61 (10.9) 27.4 (3.9) 87 0 
 
Low DS GW406381 60.3 (9.4) 30.7 (6.5) 67 <1 
 
Placebo 60.1 (9.9) 29.7 (5.2) 71 <1 
 
CXA30009 
     
None 
High DS GW406381 52.9 (11.6) 27 (5.7) 91 47 
 
Placebo 51.4 (11.3) 26.9 (5.9) 86 42 
 
Low DS GW406381 52.7 (11.8) 26.8 (5.4) 82 39 
 
Placebo 52.3 (11.6) 26.4 (4.8) 87 36 
 
BEL110751 
     
None 
High DS Belimumab 38.6 (9.3) 27 (5.5) 96 86 
 
Placebo 41.3 (11) 26.8 (6) 89 91 
 
Low DS Belimumab 40.5 (11.6) 27.4 (7.9) 94 83 
 
Placebo 39.8 (12.1) 26.5 (6) 93 85 
 
BEL110752 
     
None 
High DS Belimumab 36 (10.9) 24.2 (4.8) 97 98 
 
Placebo 40.6 (11.9) 24.4 (4.7) 89 96 
 
Low DS Belimumab 35 (10.7) 24 (4.7) 95 97 
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Placebo 35.3 (11.6) 24.1 (4.6) 95 96 
 
LBS02 
     
None 
High DS Belimumab 40.6 (8.8) 30.4 (8.3) 93 84 
 
Placebo 40.2 (10.8) 32.9 (10.9) 100 80 
 
Low DS Belimumab 42.2 (11.6) 29.5 (7.8) 94 78 
 
Placebo 42.4 (10.9) 30.7 (7.2) 89 83 
 
KIP112967 
     
None 
High DS Losmapimod 50.9 (15.9) 26.4 (7.4) 64 0 
 
Placebo 57.6 (10.1) 29.1 (5.4) 64 0 
 
Low DS Losmapimod 52.6 (13.9) 28.5 (6.2) 64 0 
 
Placebo 49.9 (13.3) 26.9 (4.7) 61 0 
 
KIP113049 
     
None 
High DS Losmapimod 57.3 (10.2) 28 (3.3) 89 0 
 
Placebo 50.1 (5.3) 29.6 (6.1) 43 0 
 
Low DS Losmapimod 58.7 (11.2) 29 (4.5) 58 2 
 
Placebo 59.3 (11) 28.9 (5.1) 48 0 
 
 
 
Supplementary Table 2: Patient demographics and concomitant corticosteroid use 
for each trial. We report demographic information on age, body mass index (BMI), sex, 
and corticosteroid use for each trial, stratified by treatment and high depressive symptom 
cutoff. We report the significance in the statistical model fitting age, bmi, sex and 
corticosteroid use for each covariate among patients with high depressive symptoms as 
described in the Supplementary Methods. 
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 Clinical Trial 
Accession 
Number 
High Depressive 
Symptoms 
 
Low Depressive 
Symptoms 
Mean(SD) 
P-Value 
(Wilcoxon) 
Treatment 
Spearman  
r (p-value)  
 
Placebo 
Spearman 
r (p-value)  
 Mean±SD N Mean±SD N 
CRP 
(mg/L) 
C016T37 16.0 ± 25.3  13.5 ± 18.5  0.9 -0.03 (0.88) 0.11 (0.65) 
C0168T41 24.9 ± 29.0  24.1  ±  24.0  0.6 -0.04 (0.66) 0.33 (0.008) 
C0524T03 21.5 ± 23.6  17.5 ± 19.4  0.3 0.10  (0.50) -0.29 (0.49) 
C0524T09 3.81± 3.97  4.27± 4.61  0.9 0.23 (0.44) NA 
C0743T08 15.4± 34.2  7.1± 9.1  0.03 0.01 (0.95) -0.01 (0.98) 
C0743T08 10.1± 18.5  7.1± 11.8  0.003 -0.07 (0.33) -0.03 (0.80) 
C1377T04 26.2 ± 24.5  25.0 ± 21.1  0.9 -0.23 (0.21) 0.01 (0.98) 
MCD2001 66.1 ± 62.6  29.1 ± 41.2  0.03 -0.38 (0.25) 0.11 (0.89) 
TNF-a  
(pg/ml) 
C0524T03 5.21± 3.38  4.42± 2.13  0.35 0.18 (0.47) NA 
IL-6 
(pg/ml) 
C0524T03 4.08± 4.38  4.06± 4.70  0.97 0.15 (0.54) NA 
C1377T04 25.6 ± 37.3  25.2 ± 62.3  0.52 -0.13 (0.49) -0.12 (0.75) 
MCD2001 9.5 ± 7.6  7.6 ± 8.3  0.18 -0.33 (0.36) 0.63 (0.37) 
*hs-CRP. C524T03, placebo arm too small (N=2) for correlation analysis of TNF-a and IL-6. 
 
Supplementary Table 3: Baseline biomarkers. Left: Baseline biomarkers are shown 
for high depressive symptom and low-depressive symptom cohorts. Right: For patients 
with high depressive symptoms at baseline, the partial Spearman correlation between 
baseline biomarker value and change in depressive symptoms, corrected for change in 
primary disease symptom severity. P-values are two-sided. 
 
